Digital Combatting longstanding challenges in rare disease detection... Approximately 350 million people are living with up to 8,000 rare diseases worldwide.
Digital The optimal mix of AI and human interactions for healthcare ... Pharmaceutical firms all around the world are investing in AI technology alongside human experts to help provide satisfying HCP engagement experiences
R&D Is biotech ready for the lecanemab opportunity? The US Veterans Health Administration recently announced that it will cover the cost of Biogen’s lecanemab for veterans suffering from early stages of Alzheimer’s disease.
Digital When will “digital health” just become health? Despite the significant drop in funding in 2022, digital health is here to stay.
R&D BioGPT: A game-changer for pharma and healthcare ChatGPT has already made waves and has been deployed to write codes, new poems, songs, recipes, and whatnot.
Digital The digital skills pharma leaders need in 2023 Pharma companies are needing to look at cost-effective ways to stay ahead of the competition.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
